CoChat

Continuous glucose monitoring in patients with type 2 diabetes treated with glucagon‐like peptide‐1 receptor agonist dulaglutide in combination with prandial insulin lispro: an AWARD ‐4 substudy

Jendle, Johan, Testa, Marcia A., Martin, Sherry, Jiang, Honghua, Milicevic, Zvonko · 2016 · Diabetes, Obesity and Metabolism
Cited by 47

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Aim: To conduct a substudy, using 24‐hour continuous glucose monitoring ( CGM ), of the AWARD ‐4 trial, which was designed to compare insulin + glucagon‐like peptide‐1 receptor agonist treatment with an insulin‐only regimen. Methods: The AWARD ‐4 trial randomized 884 conventional insulin regimen‐treated patients to dulaglutide 1.5 mg, dulaglutide 0.75 mg and glargine, all in combination with prandial insulin lispro. The CGM substudy included 144 patients inserted with a Medtronic CGMS iPro CGM device to enable 3‐day glucose monitoring. CGM sessions were completed at weeks 0, 13, 26 and 52. CGM measures included mean 24‐hour glucose, percentage time in target glucose ranges, hyper‐ and hypoglycaemia and glucose variability. The primary objective was treatment comparison for percentage time spent with CGM glucose values in the 3.9‐7.8 mmol/ L range after 26 weeks. Results: At week 26, mean CGM values decreased in all treatment groups (change from baseline −2.8 ± 0.3, −2.4 ± 0.3 and −2.5 ± 0.3 mmol/ L for dulaglutide 1.5 mg, dulaglutide 0.75 mg and glargine, respectively); between‐group differences were not statistically significant. Treatment groups were similar for percentage time in the 3.9‐7.8 mmol/ L range. Percentage time in the 3.9‐10.0 mmol/L range was greater for dulaglutide 1.5 mg than for glargine (p < 0.05). Dulaglutide and glargine were associated with decreased glucose variability for all CGM variability indices. The overall within‐patient standard deviation (s.d.) was significantly reduced with dulaglutide 1.5 mg versus glargine (p < 0.05). At week 52, there were no significant differences among the groups with regard to measures of normoglycaemia or near‐normoglycaemia and for the overall within‐patient s.d. Treatment with glargine was associated with greater increases in percentage time spent with glucose values ≤3.9 mmol/ L , with statistically significant differences between the groups at 52 weeks (p < 0.05). Conclusions: In combination with prandial lispro, treatment with dulaglutide and glargine resulted in similar proportions of glucose values in the normoglycaemic range, but dulaglutide provided an improved balance between the proportion of values within the near‐normoglycaemia range and values within the hypoglycaemic range.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12705

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 47

Metadata

Authors
Jendle, J., Testa, M. A., Martin, S., Jiang, H., & Milicevic, Z.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2016-07-22
Volume
18
Issue
10
Pages
999-1005
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2409477315
Cited by
47
References
7
FWCI
5.48
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Continuous glucose monitoring in patients with type 2 diabetes treated with glucagon‐like peptide‐1 receptor agonist dulaglutide in combination with prandial insulin lispro: an AWARD ‐4 substudy. https://app.cochat.ai/papers/10.1111/dom.12705
The paper
Jendle, J., Testa, M. A., Martin, S., Jiang, H., & Milicevic, Z. (2016). Continuous glucose monitoring in patients with type 2 diabetes treated with glucagon‐like peptide‐1 receptor agonist dulaglutide in combination with prandial insulin lispro: an AWARD ‐4 substudy. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12705

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.